Moody National Bank Trust Division grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 1.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,533 shares of the pharmaceutical company’s stock after purchasing an additional 48 shares during the period. Moody National Bank Trust Division’s holdings in Vertex Pharmaceuticals were worth $1,713,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also modified their holdings of VRTX. Truvestments Capital LLC raised its holdings in shares of Vertex Pharmaceuticals by 30.3% in the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock valued at $40,000 after buying an additional 23 shares during the period. Spinnaker Trust raised its holdings in shares of Vertex Pharmaceuticals by 2.1% in the 4th quarter. Spinnaker Trust now owns 1,235 shares of the pharmaceutical company’s stock valued at $497,000 after buying an additional 25 shares during the period. Strategic Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals by 0.6% in the 4th quarter. Strategic Advisors LLC now owns 4,486 shares of the pharmaceutical company’s stock valued at $1,807,000 after buying an additional 25 shares during the period. Moors & Cabot Inc. raised its holdings in shares of Vertex Pharmaceuticals by 0.7% in the 4th quarter. Moors & Cabot Inc. now owns 3,603 shares of the pharmaceutical company’s stock valued at $1,451,000 after buying an additional 25 shares during the period. Finally, Sculati Wealth Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 1.0% in the 4th quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company’s stock valued at $1,029,000 after buying an additional 25 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.
Insider Activity at Vertex Pharmaceuticals
In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the sale, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. This trade represents a 10.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.
Vertex Pharmaceuticals Trading Up 0.4%
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the company earned $4.76 earnings per share. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the company. Scotiabank cut their price objective on Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating on the stock in a report on Tuesday, May 6th. Barclays boosted their price objective on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. Wall Street Zen upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 11th. Truist Financial upped their price target on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Finally, Wolfe Research downgraded Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a report on Wednesday, May 7th. Fourteen investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $515.04.
Get Our Latest Stock Analysis on VRTX
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Read More
- Five stocks we like better than Vertex Pharmaceuticals
- Where Do I Find 52-Week Highs and Lows?
- Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook
- When to Sell a Stock for Profit or Loss
- 3 Different Ways to Add Gold to Your Portfolio
- What Are the U.K. Market Holidays? How to Invest and Trade
- Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.